Profund Advisors LLC Boosts Holdings in Agios Pharmaceuticals, Inc. $AGIO

Profund Advisors LLC boosted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 163.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 39,850 shares of the biopharmaceutical company’s stock after buying an additional 24,741 shares during the period. Profund Advisors LLC’s holdings in Agios Pharmaceuticals were worth $1,085,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AGIO. Wellington Management Group LLP grew its position in Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares during the last quarter. TCG Crossover Management LLC grew its position in Agios Pharmaceuticals by 105.2% in the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after buying an additional 733,038 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Agios Pharmaceuticals in the 3rd quarter valued at $19,889,000. Erste Asset Management GmbH grew its position in Agios Pharmaceuticals by 18.8% in the 3rd quarter. Erste Asset Management GmbH now owns 2,764,900 shares of the biopharmaceutical company’s stock valued at $108,578,000 after buying an additional 438,411 shares during the last quarter. Finally, SummitTX Capital L.P. purchased a new position in Agios Pharmaceuticals in the 3rd quarter valued at $10,556,000.

Agios Pharmaceuticals News Roundup

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Zacks Research raised its FY2026 earnings estimate for Agios Pharmaceuticals, implying a slightly better near-term outlook for the company. AGIO Free Report
• Positive Sentiment: The firm also lifted its FY2027 EPS estimate, another signal that analysts see some improvement in Agios’ longer-term profitability trajectory. AGIO Free Report
• Positive Sentiment: Several quarterly estimates were nudged higher, including Q2 2026, Q3 2026, Q2 2027 and Q3 2027, which may be supporting sentiment around the company’s earnings outlook. AGIO Free Report
• Neutral Sentiment: Other updates were mixed, with Zacks trimming its Q1 2027 and Q1 2028 EPS estimates and lowering FY2028 expectations, offsetting some of the more upbeat revisions. AGIO Free Report
• Negative Sentiment: The company still faces meaningful losses in the forecast period, with analysts expecting negative EPS through at least 2028, which underscores ongoing profitability risk. AGIO Free Report

Insider Transactions at Agios Pharmaceuticals

In related news, insider James William Burns sold 3,280 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,848.80. Following the completion of the transaction, the insider owned 49,306 shares of the company’s stock, valued at approximately $1,711,411.26. The trade was a 6.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Cecilia Jones sold 3,141 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $109,024.11. Following the completion of the transaction, the chief financial officer directly owned 54,998 shares of the company’s stock, valued at $1,908,980.58. The trade was a 5.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 15,582 shares of company stock worth $520,405 in the last ninety days. Company insiders own 5.40% of the company’s stock.

Analyst Ratings Changes

AGIO has been the topic of a number of analyst reports. Bank of America lowered their price objective on shares of Agios Pharmaceuticals from $44.00 to $41.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. The Goldman Sachs Group lifted their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. Truist Financial lowered their price objective on shares of Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, April 30th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Friday, March 27th. Finally, Citigroup boosted their target price on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $41.56.

Agios Pharmaceuticals Stock Up 1.0%

Agios Pharmaceuticals stock opened at $28.79 on Friday. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00. The firm’s 50-day simple moving average is $29.61 and its 200 day simple moving average is $29.57. The firm has a market capitalization of $1.71 billion, a PE ratio of -3.97 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The firm had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.30 million. The company’s revenue was up 137.7% compared to the same quarter last year. On average, research analysts expect that Agios Pharmaceuticals, Inc. will post -6.17 EPS for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.